Drug therapy for alveolar soft part sarcoma: current status and progress

杨凌舸; 王春萌

doi:10.19401/j.cnki.1007-3639.2019.09.010

您当前的位置：

首页 >

文章列表页 >

Drug therapy for alveolar soft part sarcoma: current status and progress

更新时间：2026-01-27

- Drug therapy for alveolar soft part sarcoma: current status and progress
- China Oncology Vol. 29, Issue 9, Pages: 746-752(2019)
- 作者机构：
  
  复旦大学附属肿瘤医院骨软组织外科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2019.09.010
  CLC： R738.6
- Published Online：20 November 2019，
  
  Published：20 November 2019
- 稿件说明：
移动端阅览
杨凌舸, 王春萌. 腺泡状软组织肉瘤药物治疗现状与进展[J]. 中国癌症杂志, 2019, 29(9): 746-752.

杨凌舸, 王春萌. Drug therapy for alveolar soft part sarcoma: current status and progress[J]. China Oncology, 2019, 29(9): 746-752.
杨凌舸, 王春萌. 腺泡状软组织肉瘤药物治疗现状与进展[J]. 中国癌症杂志, 2019, 29(9): 746-752. DOI： 10.19401/j.cnki.1007-3639.2019.09.010.

杨凌舸, 王春萌. Drug therapy for alveolar soft part sarcoma: current status and progress[J]. China Oncology, 2019, 29(9): 746-752. DOI： 10.19401/j.cnki.1007-3639.2019.09.010.

摘要

腺泡状软组织肉瘤是一种较罕见的恶性肿瘤，尽管有60余年的临床治疗经验，但该肿瘤的组织学起源、发病危险因素、临床特征和最佳治疗方案等仍不太明确。近10余年来，许多学者对该肿瘤进行了大量研究。对此期间发表的相关文献，围绕靶向治疗与免疫治疗中免疫检查点抑制剂的应用现状与进展进行综述，旨在总结和寻找其治疗的新途径和新方法。

Abstract

Alveolar soft part sarcoma is a rare malignant tumor. Although there are more than 60 years of experience in clinical treatment

the tumor’s histological origin

risk factors

clinical progression and the best treatment scheme are not very clear. In the past 10 years

many scholars have carried out a lot of research on this tumor. In this review

we discussed recent publications related to alveolar soft part sarcoma in order to better understand and search for new ways to treat this disease with targeted therapy and immune checkpoint inhibitor therapy.

关键词

Keywords

references

Views

3361

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress and prospect on treatment for radioiodine-refractory thyroid cancer

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

Clinical characteristics and prognosis of severe immune checkpoint inhibitors-related liver injury in gastrointestinal malignancies

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Related Author

Qianqian GENG

Aimin YANG

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

GAO Hongsheng

ZHANG Ruixing

Related Institution

Department of Nuclear Medicine, The first affiliated hospital of Xi’an Jiao Tong University

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

AI问答

⁰